AGP Picks
View all

Lumea adds Nonagen’s bladder cancer test suite to digital diagnostics platform

Oct. 27, 2026
Lumea adds Nonagen’s bladder cancer test suite to digital diagnostics platform
By AI, Created 12:00 UTC, Oct 27, 2026, AGP -

Lumea has integrated Nonagen Bioscience’s Oncuria bladder cancer tests into its digital diagnostics platform, giving urologists access to urine-based testing inside existing workflows. The move is designed to support detection, surveillance and treatment planning for bladder cancer patients without forcing clinicians out of their standard reporting systems.

Why it matters: - The integration puts non-invasive bladder cancer testing inside the same workflow urologists already use for ordering and reporting. - The Oncuria suite is built to support faster risk stratification alongside cystoscopy and imaging. - Lumea and Nonagen are targeting a common pain point in cancer care: making advanced diagnostics easier to use in day-to-day practice.

What happened: - Lumea announced the integration of Nonagen Bioscience’s Oncuria suite into its digital diagnostics platform on Oct. 27, 2026. - The rollout covers three urine-based tests: Oncuria Detect, Oncuria Monitor and Oncuria Predict. - The companies said the tests are accessible directly within urologists’ established reporting and testing workflows.

The details: - Oncuria Detect is designed for patients without a prior bladder cancer history who present with gross or microscopic hematuria or suspected urothelial carcinoma. - Oncuria Monitor is intended for ongoing surveillance of patients with known bladder cancer, especially non-muscle invasive bladder cancer. - Oncuria Predict is used to assess the likelihood of response to intravesical BCG therapy in newly diagnosed non-muscle invasive bladder cancer cases. - The Oncuria platform combines multiplex urine-based biomarker testing with proprietary AI-driven algorithms to generate risk assessments. - The assays are positioned as high-sensitivity rule-out tests with high negative predictive value. - The tests are meant to help clinicians risk-stratify patients alongside standard-of-care procedures such as cystoscopy and imaging. - Lumea’s platform embeds requisition requirements into the physician workflow and prompts for the clinical factors needed for each assay. - The system is designed to help ensure the correct Oncuria test and analytical model are used for each patient scenario. - Lumea CEO James Thackeray said the goal is to unify the diagnostic ecosystem so physicians can use evidence-based tools without leaving their workflow. - Nonagen CEO Dr. Charles Rosser said the assays were engineered to deliver high negative predictive value so clinicians can rule out disease and tailor care.

Between the lines: - The partnership signals a push toward tighter software-and-diagnostics integration in urology, where test selection and interpretation can vary by patient history and treatment stage. - By embedding ordering logic into the platform, Lumea and Nonagen are trying to reduce friction and improve test matching, not just add another test menu item. - The arrangement also reflects growing interest in AI-assisted diagnostics that support clinical decisions without replacing standard procedures.

What's next: - Lumea and Nonagen said clinicians can learn more or request a platform demonstration through LumeaDx.com and nonagen.com. - The companies indicated the integrated tools are being positioned for daily use across urology practices in the U.S. - Further adoption will likely depend on how smoothly the workflow integration performs in real clinical settings.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

IT Press Releases

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

IT Press Releases

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.